Galapagos Achieves Milestones in Two Strategic Alliances
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Galapagos NV announces achievement of milestones totaling €2.5 million in two of its strategic alliances.
In the alliance with Janssen Pharmaceutica NV (Janssen) in rheumatoid arthritis, Galapagos received a milestone payment of €1.5 million. To date, Galapagos has earned more than €24 million in payments from Janssen under this alliance.
In Galapagos' alliance with GlaxoSmithKline (GSK) in the area of infectious diseases, Galapagos received a €1 million milestone payment. Since initiation of this alliance at the end of 2007, Galapagos has received a total of €6 million under the anti-infectives alliance with GSK.
"Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in R&D revenues," said Onno van de Stolpe, CEO of Galapagos.
In the alliance with Janssen Pharmaceutica NV (Janssen) in rheumatoid arthritis, Galapagos received a milestone payment of €1.5 million. To date, Galapagos has earned more than €24 million in payments from Janssen under this alliance.
In Galapagos' alliance with GlaxoSmithKline (GSK) in the area of infectious diseases, Galapagos received a €1 million milestone payment. Since initiation of this alliance at the end of 2007, Galapagos has received a total of €6 million under the anti-infectives alliance with GSK.
"Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in R&D revenues," said Onno van de Stolpe, CEO of Galapagos.